MALADIE CORONAIRE ET INSUFFISANCE CARDIAQUE : APPROCHE GENOTYPIQUE DU TRAITEMENT.

[en] Phenotypic approach of the treatment of coronary artery disease and heart failure used in prospective randomized trials has contributed to significantly improve patieni prognosis. However, gene polymorphisms have been shown to be able to alter treatment efficacy with anti-platelets, beta-blockers or ACE-inhibitors in these settings. As suggested by several studies, therapeutic approaches based on genotype should contribute to personalize treatments with better efficacy and safety.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Lancellotti, Patrizio ; Université de Liège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie

ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie

Language :

French

Title :

MALADIE CORONAIRE ET INSUFFISANCE CARDIAQUE : APPROCHE GENOTYPIQUE DU TRAITEMENT.

Alternative titles :

[en] CORONARY ARTERY DISEASE AND HEART FAILURE: A GENOTYPE-BASED THERAPEUTIC APPROACH

Publication date :

2015

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

5-6

Pages :

282-5

Peer reviewed :

Peer reviewed

Available on ORBi :

since 03 December 2015

Statistics

Number of views

172 (7 by ULiège)

Number of downloads

188 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Voora D, Ginsburg GS., Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol, 2012, 60, 9-20.
Mestroni L, Begay R, Graw SL, et al., Pharmacogenetics of heart failure. Curr Opin Cardiol, 2014, 29, 227-234.
Weeke P, Roden DM., Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med, 2014, 65, 81-94.
Scheen AJ, Descamps OS., Approche personnalisée du traitement des dyslipidémies. Rev Med Liège, 2015, 70, 292-298.
Yusuf S, Zhao F, Mehta SR, et al., Clopidogrel in unstable angina to prevent recurrent events. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, 345, 494-502.
Gurbel PA, Becker RC, Mann KG, et al., Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol, 2007, 50, 1822-1834.
Shudiner AR, O'Connel JR, Bliden KP, et al., Association of cytochrome P450 2C19 genotype with antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 2009, 302, 849-857.
Simon T, Verstuyft C, Mary-Krause M, et al., Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009, 360, 363-375.
Sibbing D, Koch W, Gebhard D, et al., Cytochrome 2C19∗17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-Treated patients with coronary stent placement. Circulation, 2010, 121, 512-518.
Wiviott SD, Braunwald E, McCabe CH, et al., The TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357, 2001-2015.
Cuisset T, Frere C, Quilici J, et al., Benefit of a 600 mg loading dose of clopidogrel on paltelet reactivity and clinical outcomes in patients with non-ST elevation coronary syndrome undergoing coronary stenting. J Am Coll Cardiol, 2006, 48, 1339-1345.
Bonello L, Camoin-Jau L, Arques S, et al., Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol, 2008, 51, 1404-1411.
Roberts JD, Wells GA, Le May MR, et al., Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial. Lancet, 2012, 379, 1705-1711.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONCENSUS Trial Study Group. N Engl J Med, 1987, 316, 1429-1435.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med, 1991, 325, 293-302.
Rutherford J, Pfeffer M, Moye L et al. -Effects of captopril on ischaemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation, 1994, 90, 1731-1738.
Fox KM. -The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease; randomized double-blind, placebo-controlled multicenter trial (the EUROPA study). Lancet, 2003, 362, 782-788.
Van der Leeuw J, Oemrawsingh RM, Van der Graaf Y, et al., Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease -Results from EUROPA. Int J Cardiol, 2015, 182, 194-199.
CIBIS-II Investigators and Committees., The cardiac insufficiency Bisoprolol II (CIBIS II): A randomized trial. Lancet, 1999, 353, 9-13.
MERIT-HF Study Group., Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet, 1999, 353, 2001-2007.
Rau T, Heide R, Bergmann K, et al., Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-Term treatment. Phamacogenetics, 2002, 12, 465-472.
Raud T, Wuttke H, Michels LM, et al. -Impact of the CYP2D6 genotype on clinical effects of metoprolol: A prospective longitudinal study. Clin Pharmacol Ther, 2009, 85, 269-272.
Nozawa T, Taguchi M, Tahara K, et al., Impact of CYP2D6 genotype on metoprolol plasma concentration and beta-Adrenergic inhibition during long-Term treatment : A comparison with bisoprolol. J Cardiovasc Pharmacol, 2005, 46, 713-720.
Oldham HG, Clarke SE., In vitroidentification of the human cytochrome P450 enzymes envolved in the metabolism of R(+)-And S(-)-carvedilol. Drug Metab Dispos, 1997, 25, 970-977.
White HL, de Boer BA, Maqbool A, et al., An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: A MERIT-HF sub-study. Eur J Heart Fail, 2003, 5, 463-468.
De Groote P, Lamblin N, Helbecque N, et al., The impact of beta-Adrenergic receptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail, 2005, 7, 966-973.